Benzinga | Nov 8, 2021 05:42AM EST

Edwards' Transcatheter Tricuspid Replacement System Shows Favorable Patient Outcomes

* Edwards Lifesciences Corporation (NYSE:EW) announced results from the TRISCEND study of its EVOQUE transcatheter tricuspid valve replacement system.

* Patients enrolled in the TRISCEND study had symptomatic, moderate, or greater functional or degenerative tricuspid regurgitation (TR), despite optimal medical therapy.

* The 6-month results (n=56) demonstrated significant TR reduction by core laboratory assessment.

* A significant reduction in TR severity was observed, with 100% of patients with none/trace or mild TR in 43 patients with paired echocardiographic data available.

* Significantly improved functional and quality-of-life outcomes were seen.

* Data showed a survival rate of 96% and freedom from heart failure hospitalization rate of 94%.

* The EVOQUE valve replacement system is an investigational device and is not available for sale in any country.

* Price Action: EW shares closed at $118.65 on Friday.